Presentation Description: The COVID-19 pandemic has amplified the need for inhaled prophylaxis and therapy of infections affecting initially or primarily the respiratory tract. Compared to oral administration, direct aerosol delivery to the respiratory tract can achieve very high drug concentration where the infectious pathogens reside while resulting in relatively low systemic drug exposure and thus low potential for side effects. There are several approved inhaled anti-infectives on the market setting useful precedents for future developments. This presentation will discuss inhalation formulations and devices suitable for convenient self-administration for pandemic situations. The options for rapid development of new or repurposed prophylactic and therapeutic modalities for COVID19 will be outlined.
Understand the rationale for the advantages of the inhaled route of administration to treat pandemic infections like COVID-19
Consider the opportunities to repurpose established safe and effective drugs for delivery via the inhalation route vs new chemical entities.
Understand the use of animal models to evaluate inhaled products to treat respiratory infection pandemics
Selecting options for formulations and devices based on the target patient population and the constraints of your drug properties